OR2-002 – The risk of FMF in MEFV heterozygotes

IntroductionFamilial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disorder due to MEFV mutations and one of the most frequent Mediterranean genetic diseases. The observation of many heterozygous patients in whom a second mutated allele was excluded led to propose that heteroz...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric rheumatology online journal 2013-11, Vol.11 (S1), p.A2-A2, Article A2
Hauptverfasser: Jéru, I, Hentgen, V, Cochet, E, Duquesnoy, P, Le Borgne, G, Grimprel, E, Stojanovic, K Stankovic, Karabina, S, Grateau, G, Amselem, S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:IntroductionFamilial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disorder due to MEFV mutations and one of the most frequent Mediterranean genetic diseases. The observation of many heterozygous patients in whom a second mutated allele was excluded led to propose that heterozygosity could be causal; however, this might often be coincidental due to the very high rate ofmutations in Mediterranean populations.ObjectivesTo better delineate the pathogenicity of heterozygosity in order to help genetic counselling and better manage the disease.MethodsComplementary statistical approaches were used: estimation of FMF prevalence at population levels, genotype comparison in siblings from 63 familial forms, and genotype study in 557 patients from four Mediterranean populations.ResultsAt population level, we did not observe any contribution of heterozygosity to the disease prevalence. In affected siblings of patients carrying two MEFV mutations, 92% carry two mutated alleles whereas 4% are heterozygous with typical FMF diagnosis. We also demonstrated statistically that patients are more prone to be heterozygous than healthy individuals, as shown by the higher ratio heterozy-gous carriers/non carriers in patients (p
ISSN:1546-0096
1546-0096
DOI:10.1186/1546-0096-11-S1-A2